Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Unless you are a day trader

<< Previous

Bullboard Posts

Next >>

Comment by Actuarialon Apr 20, 2021 3:59pm

290 Views

Post# 33031025

RE:RE:Unless you are a day trader

Funding is sufficient regardless whether it is on schedule or not. ATE is small company with little general expense (i.e., salary, benefits, etc.). Clinical trials, IND filings are costly but ATE would not expense it until clinical trials actually happens.

<< Previous

Bullboard Posts

Next >>

Mastering options Greeks: Essential knowledge for informed trading